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The imbalance between oxidants and antioxidants is known to play an important role in the pathogenesis of chronic
obstructive pulmonary disease (COPD). Cigarette smoking is the most frequent factor responsible for development
of COPD by leading to oxidant overload in the lower airways, due to presence of its own oxidants and to
recruitment and activation of pulmonary phagocytes.
We aimed to determine whether (1) patients with stable COPD have higher thiobarbituric acid-reactive substances
(TBARs, an end-product of lipid peroxidation) and H2O2 levels in expired breath condensate than healthy subjects
who have never smoked; (2) COPD subjects who are current smokers exhale more TBARs and H2O2 than COPD
ex-smokers and those who have never smoked; and (3) concentration of TBARs correlates with H2O2 levels in the
breath condensate of COPD patients.
The TBAR and H2O2 content in expired breath condensate of 17 healthy nonsmoking subjects and 44 patients (11
current smokers, 20 ex-smokers and 13 who had never smoked) with stable COPD [forced expiratory volume in 1 s
(FEV1) 63·3&16·3% and FEV1 reversibility 5·2&4·3% predicted value] was measured spectrofluorimetrically by the
thiobarbituric acid and homovanillic acid methods, respectively.
The mean concentrations of TBARs and H2O2 in the expired breath condensate of COPD subjects were 12
(0·48–0·86 ìm vs. 0·04&0·14 ìm; P<0·05) and 10 times (0·48&0·67 ìm vs. 0·05&0·07 ìm; P<0·005) higher than in
healthy controls. Current smokers with COPD did not exhale more H2O2 than COPD ex-smokers and those who
had never smoked. TBARs levels shared only a tendency to be higher in the breath condensate of smoking COPD
subjects than in that of ex-smokers (0·92&1·49 ìm vs. 0·35&0·44 ìm) and of COPD subjects who had never smoked
(0·92&1·49 ìm vs. 0·30&0·53 ìm). No correlation was found between TBAR and H2O2 levels in the whole COPD
group. These variables did not correlate with cigarette smoking status and the time from smoking cessation.
Subjects with stable COPD exhibit increased lipid peroxidation and H2O2 generation in the airways. Current
cigarette smoking does not distinguish COPD subjects with respect to TBARs and H2O2 exhalation.
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Cigarette smoking is the major factor implicated in the
pathogenesis of chronic obstructive pulmonary disease
(COPD) (1). Cigarette smokers have an increased number
of macrophages and neutrophils in the lower airways (2,3).
These cells release large amounts of hydrogen peroxide
(H2O2) (2,4) which, after conversion into hydroxyl radicals0954-6111/99/060389+08 $12.00/0(5), can cause peroxidation of the polyunsaturated fatty
acids of cell membranes (6,7). In addition, cigarette smoke
itself contains many free radicals which are capable of
reacting with biomolecules present in the airways (5,8).
Some of the H2O2 which is decomposed by antioxidant
enzymes may evaporate from the alveolar lining fluid and
may be exhaled with the expiratory air. Similarly, some
lipid peroxidation products, such as ethane, penthane and
thibarbituric acid-reactive substances (TBARs), are volatile
and may be present in expired breath (9,12). Patients with
COPD and asymptomatic cigarette smokers have been
reported to exhale more H2O2 than healthy nonsmokers
(13,14). As cigarette smoking enhances oxidant generation
in the airways (7,13) it is possible that COPD patients who? 1999 W. B. SAUNDERS COMPANY LTD
390 D. NOWAK ET AL.still smoke have higher concentration of H2O2 and lipid
peroxidation products in expired air than ex-smokers or
those COPD subjects who have never smoked. Recent
studies, however, have provided conflicting data showing
that COPD patients who still smoked could exhale lower
amounts of H2O2 than ex-smokers with stable COPD (14).
The interindividual variability in antioxidant potential (10)
or the induction by cigarette smoke of some compensatory
mechanisms providing protection against reactive oxygen
species including H2O2 (15) may be possible explanations of
this observation. On the other hand, the above-mentioned
diVerences between COPD smokers and ex-smokers in
H2O2 exhalation are based on the analysis of a small group
of patients and therefore bias cannot be excluded (14). In
addition, no studies on TBAR exhalation in COPD subjects
have been published so far. Therefore, in this study we
aimed to compare the concentration of TBARs and H2O2
in the expired breath condensate of 17 healthy nonsmoking
subjects and 44 patients with stable COPD and to investi-
gate whether the exhalation of these compounds was cor-
related with or dependent upon current smoking status. We
report here that patients with stable COPD exhale 12 and
10 times more TBARs and H2O2 than healthy nonsmoking
subjects and that these variables do not correlate with
cigarette smoking.Material and MethodsREAGENTS
Horseradish type II peroxidase (HRP, 200 U mg"1 solid),
4-hydroxy-3-methoxy-phenylacetic acid (homovanillic
acid), thiobarbituric acid (TBA) and tetramethoxypropane
were obtained from Sigma Chemical Co. (St. Louis, MO,
U.S.A.). All other compounds were purchased from POCH
(Gliwice, Poland) and were of analytical grade. Sterile
deionized water (conductivity 0·05 S cm"1, Milli Q Plus
Water Purification System, New York, U.S.A.) was used
throughout the study. Thirty per cent H2O2 solution was
diluted 100-fold with phosphate-buVered saline (PBS, pH
7·4) and stored at 4)C in the dark. An aqueous solution of
HRP (1 U ml"1) with the addition of 100 ìm homovanillic
acid was freshly prepared before the assay.STUDY POPULATIONS
The study subjects included 17 healthy volunteers and 44
patients with COPD (Table 1) who had not suVered from
any infectious disease for at least 3 months prior to the
study. Healthy subjects who had never smoked and with no
history of respiratory or atopic disease were members of
our medical staV and were free of any medication. Routine
physical examination showed nothing abnormal. Fifty-two
patients with COPD were recruited from the Medical
University Outpatient Department COPD register. They
had not taken inhaled or oral corticosteroids for the last
3 months. Subjects were asked to stop any medication
except short-acting â2-agonists (salbutamol or fenoterol
on demand), anticholinergics (ipratropium bromide) andtheophylline and to come to the clinic after a 4-week
wash-out period for collection of expired breath condensate
and to perform the lung function test. The intake of
mucolytics (bromhexine, ambroxol, N-acetylcysteine) was
not allowed during the study due to their possible anti-
oxidant activity (16–18). Spirometry was performed with a
Flowscreen (Erich Jaeger GmbH Co., Germany) equipped
with software compatible to American Thoracic Society
standards (19) between 0900 and 1100 hours and subjects
refrained from the use of inhaled drugs (â2-agonists and
anticholinergics) and oral theophylline for 6 and 12 h
before lung function measurement, respectively. The inclu-
sion criteria were the ability to stop other than the above
recommended therapy and a forced expiratory volume in
1 s (FEV1) increase below 10% of the predicted value
15 min after 200 ìg of salbutamol (two puVs from the
metered dose inhaler). Forty-four of the COPD patients
fulfilled these criteria. Eleven of them were current smokers,
20 were ex-smokers and 13 had never smoked (Table 2). All
patients were asked about their smoking and disease history
and their medical documentation was carefully analysed.
Patients had not suVered from any COPD exacerbation
during the 3 months before the study. The number of
exacerbations per year during the 2 years prior to the visit
date in the whole COPD group ranged from 1 to 8 (mean
3&2). In current smokers, ex-smokers and those COPD
patients who had never smoked, the mean number of
exacerbations per year reached 3&1, 3&2 and 3&2,
respectively. The duration of COPD varied from 24 to 436
months (mean 115&91) for the whole group and 71&51,
150&107 and 98&71 months for current smokers,
ex-smokers and COPD patients who had never smoked,
respectively. This study was approved by the Medical
University Ethics Committee and all subjects gave informed
consent before participation.COLLECTION OF AIR CONDENSATE
The expired breath condensate was collected just before the
lung function tests as described previously (12,13). Briefly,
patients were asked to breathe out spontaneously through aTable 1. Characteristics of study subjects
Subjects who had
never smoked
COPD
patients
n 17 44
Age (years) 55&7 60&9
Sex (M:F) 10:7 23:21
FEV1 (%) 99&4 63·3&16·3*
FEV1/FVC 80·3&1·4 57·8&13·9*
FEV1 reversibility (%) 1·3&1·2 5·2&4·3
FEV1 and FEV1 reversibility are expressed as % predicted.
All data are expressed as mean&sd.
*P<0·01 vs. appropriate value of normal subject.
FVC, forced vital capacity.
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The concentration of H2O2 in expired breath condensate
was measured according to the method of Ruch et al. (22).
Briefly, 600 ìl of expired breath condensate was mixed with
600 ìl of HRP solution (1 U ml"1) containing 100 ìm
homovanillic acid and was incubated for 60 min at 37)C.
Then, the sample was mixed with 150 ìl 0·1 m glycine–
NaOH buVer (pH 12·0) with the addition of 25 mm EDTA.
The homovanillic acid oxidation product, as a measure of
the amount of H2O2, was determined spectrofluorimetri-
cally using a Perkin Elmer Luminescence SpectrometerLS-50B (Norwalk, CT, U.S.A.). Excitation was at 312 nm
and emission was measured at 420 nm. As opposed to our
previous studies (in which the results were expressed in
nanomoles of H2O2 per sample) (12,13) readings were
converted into ìm using the regression equation y=(x–x0)
0·06764 (where y=micromoles of H2O2 per litre of expired
breath condensate; x=intensity of emission at 420 nm
expressed in arbitrary units and; x0=intensity of emission
given by reference sample receiving distilled water instead
of breath condensate). The lower limit of H2O2 detection
was 83 nm and the calibration curve was linear up to an
H2O2 concentration of 16·7 ìm.MEASUREMENT OF TBA-REACTIVE PRODUCTS
TBARs are low molecular weight compounds formed via
the decomposition of certain primary and secondary lipid
peroxidation products which at low pH and elevated tem-
perature participate in a nucleophilic addition reaction with
thiobarbituric acid, generating a red fluorescent complex.
Malondialdehyde (MDA) is one of the most important
TBARs (9). The content of TBARs in breath condensate
was determinated as previously described (12), except that
results are here expressed in ìm instead of nanomoles per
sample. Briefly, 100 ìl of the condensate were mixed with
2 ml of TBA solution (0·67 g dissolved in 100 ml of
deionized water, then diluted 1:1 with glacial acetic acid),
boiled for 30 min and allowed to cool at ambient tempera-
ture, next, chromogen was extracted into 2·5 ml of butanol
by vigorous shaking for 1 min. Following centrifugation
(10 min, 1500 g, 25)C), TBARs were measured spectro-
fluorimetrically (excitation 515 nm, emission 546 nm) (23).
Readings were converted into ìm using the regression
equation y=0·12 x"0·07 (where y=ìm of TBARs and
x=intensity of emission at 546 nm expressed in arbitrary
units) obtained from three series of experiments with 20mouthpiece with a saliva trap connected to the tube and to
breathe in with the mouthpiece removed, for 20 min. The
collecting part of the tube was covered with ice and salt.
The temperature in the tube vicinity ranged from "6 to
0)C and allowed condensation of all H2O2 present in the
expiratory air (20). Each subject wore a noseclip and rinsed
their mouth with distilled water just before and at 7 and
14 min of collection in order to reduce the H2O2 evapor-
ation from saliva (20) and the nasal spaces (13). At the end
of collection, the tube was removed from the container and
2–5 ml aliquots of condensate were transferred to
Eppendorf tubes and stored at "80)C for not more than
7 days until H2O2 and TBARs measurement. All collections
were performed between 0800 and 0900 hours. Cigarette
smoke itself causes formation of reactive oxygen species in
aqueous solution and expired breath (5,21). Therefore, our
smokers refrained from cigarette smoking for 12 h before
the visit. If the patient failed to refrain from smoking or to
stop medication (as described above), the breath conden-
sate was not collected and the visit was rescheduled within
1–7 days. This procedure allowed us to conclude that H2O2
levels in breath condensate reflected the intensity of H2O2
production in the airways (13).Table 2. Characteristics of COPD patient subgroups
Current smokers Ex-smokers* Never smoked†
n 11 20 13
Age (years) 53&10 65&6 60&9
Sex (M:F) 6:5 13:7 4:9
Present cigarette consumption 14&7 0 0
Cumulative cigarette consumption 23·0&14·6 26·0&19·2 0
FEV1 (%) 64·5&13·7 63·6&17·8 62·0&17·0
FEV1/FVC 59·1&8·2 55·3&15·8 60·5&14·9
FEV1 reversibility (%) 5·6&3·3 5·0&4·1 5·1&2·9
FEV1 and FEV1 reversibility are expressed as % predicted.
All data are expressed as mean&sd.
*Time from smoking cessation varied from 6 to 369 months (mean 116&104 months).
†The COPD patients who had never smoked were professionally exposed for more than 20 years to
factors that are known to predispose to COPD. Of the men, one was a welder, the second a grinder
and two were workers in a coal merchant’s shop. The women were textile industry workers (in
dye-works, warehouse with chemicals or the spinning room).
FVC, forced vital capacity.
392 D. NOWAK ET AL.STATISTICAL ANALYSIS
Data from subjects are expressed as mean&sd. For read-
ings which gave results before the method sensitivity, the
H2O2 and TBAR concentration in expired breath conden-
sate was assumed to be 0 nm. The diVerences between
results found in healthy subjects and COPD patients were
determined by analysis of variance (ANOVA). A P-value of
less than 0·05 was considered to be significant. Pearson’s
correlation was used to determine the relationships between
measured variables. All calculations were performed using
Microsoft Excel version 5·0 software.ResultsH2O2 AND TBAR LEVELS IN HEALTHY
SUBJECTS
In healthy nonsmoking subjects the mean H2O2 concen-
tration in expired breath condensate was 0·05&0·07 ìm
(n=17) (Fig. 1). In 11 (65%) healthy controls (seven men,
four women), no detectable H2O2 concentration was
noted. TBARs results were positive only in two of 17
healthy volunteers. The means TBAR concentration in
breath condensate for the control group was 0·04–0·14 ìm
(Fig. 2).Current
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Fig. 1. H2O2 concentration in the expired breath conden-
sate of healthy ( , never smoked) and COPD ( , never
smoked; 4, ex-smokers; 0, current smokers) subjects.
Individual results below the sensitivity of H2O2 method
determination (0·083 ìm) were assumed to be 0 ìm. The
mean H2O2 concentration in the whole COPD group was
0·48&0·67 ìm. *Significantly diVerent from value found
for healthy controls who had never smoked; P<0·05.Current
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Fig. 2. Concentration of TBARs in the expired breath
condensate of healthy ( , never smoked) and COPD ( ,
never smoked; 4, ex-smokers; 0, current smokers). Indi-
vidual results below the sensitivity of TBARs method
determination (0·05 ìm) were assumed to be 0 ìm. The
mean TBAR concentration in the whole COPD group
was 0·48&0·86 ìm. Significantly diVerent from value
found for healthy controls who had never smoked;
*P<0·05; **P<0·01.H2O2 AND TBAR LEVELS IN COPD SUBJECTS
Patients with stable COPD exhibited a 10-times higher
concentration of H2O2 (P<0·005) than healthy nonsmoking
subjects. The mean H2O2 level in the expired breath con-
densate reached 0·48&0·67 ìm (n=44). However, 16 (36%)
COPD patients (nine men, seven women) revealed no
detectable H2O2 levels (Fig. 1). Four of them were current
smokers, nine ex-smokers and three had never smoked.
Mean H2O2 levels in the expired breath condensate in
COPD patients who were current smokers did not diVer
significantly from that found in COPD ex-smokers
(0·41&0·54 ìm vs. 0·55&0·76 ìm). Patients who had never
smoked had 0·44&0·65 ìm H2O2 in the expired breath
condensate. Male COPD patients showed similar H2O2
values compared with women, both in the whole COPD
group (0·46&0·62 ìm, n=23 vs. 0·51&0·69 ìm, n=21) and
in the current smokers COPD subgroup (0·27&0·34 ìm,
n=6 vs. 0·57&0·72 ìm, n=5). The mean TBARs level
in breath condensate of COPD subjects reached 0·48&
0·86 ìm and was 12 times higher (P<0·05) than that found
in healthy controls (Fig. 2). The rate of positive TBARs
readings was also higher in COPD subjects than in healthy
nonsmoking controls (0·48 vs. 0·12). Although COPD sub-
jects who were permanent smokers revealed 3·1 and 2·6
times higher mean TBARs levels in expired breath con-
densate than COPD patients who had never smoked
(0·92&1·49 ìm vs. 0·30&0·53 ìm) and COPD ex-smokers
(0·92&1·49 ìm vs. 0·35&0·44 ìm), these diVerences were
not significant, probably due to the high variability of
individual results. The rate of positive TBARs readings was
similar for all three COPD subgroups; 0·46 for subjects who100-ìl samples containing increasing (0·01–50 ìm) tetra-
methoxypropane concentrations. The lower limit of TBARs
detection was 0·05 ìm. Control experiments showed that
short-acting â2-agonists and anticholinergics which may be
exhaled and present in the breath condensate did not form
fluorescent complexes with TBA (12).
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current smokers. No significant diVerences were noted
between TBARs concentrations in COPD men and women
(0·58&0·98 ìm vs. 0·36–0·68 ìm) and also in COPD men
and women who were current smokers (1·16&1·19 ìm, n=6
vs. 0·63&1·15 ìm, n=5).
COPD subjects with detectable H2O2 in breath conden-
sate exhaled similar amounts of TBARs to those with H2O2
levels below the method sensitivity (0·43&0·67 ìm, n"8 vs.
0·57&1·14 ìm, n=16) and the rate of positive TBARs
readings in these subgroups was 0·50 and 0·56, respectively.
Only nine of 44 COPD subjects (20%) had negative read-
ings of both TBARs and H2O2, while in healthy control
group most of the analysed subjects (11 of 17; 65%)
revealed levels below the detection sensitivity.CORRELATIONS OF H2O2 AND TBARS WITH
CLINICAL STATUS, SMOKING HABITS AND
LUNG FUNCTION
Analysis of correlations of exhaled H2O2 and TBARs with
selected clinical variables showed only a few statistically
significant results (Table 3). The concentration of H2O2 in
expired breath condensate moderately correlated with
FEV1% predicted in the whole COPD group as well in the
ex-smokers and never-smoked COPD subgroups. There
was also a positive correlation between TBARs levels and
FEV1% predicted and TBARs and disease duration in
never smoked COPD subjects and former smokers with
COPD, respectively. No associations between cigarette
smoking status (present cigarette consumption, cumulative
cigarette consumption), H2O2 and TBARs were noted.
Similarly, H2O2 concentration did not correlate with
TBARs levels in breath condensate in the whole COPD
group (r= "0·02) (Fig. 3) and in the current smokers
and ex-smokers COPD subgroups (r=0·20; r= "0·34,
respectively). However, there was a strong positive
correlation between H2O2 and TBARs in the expired breath
condensate of COPD subjects who had never smoked
(r=0·85, P<0·0003).0.0
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Fig. 3. The H2O2- and TBAR-dependent distribution of
breath condensate samples from 44 COPD subjects ( )
and 17 healthy controls ( ). All samples from healthy
subjects are localized around the point of intersection of
the dashed lines showing the sensitivity of H2O2 and
TBARs methods determination. Twenty-six samples
(59%) from COPD subjects are distant from this point.
There was no correlation between H2O2 and TBAR con-
centrations in the whole COPD group. Due to overlap-
ping, the number of circles is lower than number of
analysed subjects.Discussion
We found that patients with stable COPD had much higher
mean TBARs and H2O2 concentrations in their expired
breath condensate than healthy nonsmoking subjects. Our
findings provide evidence of oxidant overload and increased
lipid peroxidation in the airways of COPD subjects and
support the hypothesis that inflammatory processes within
the airways involve free radical-mediated reactions.
Patients with lung disorders accompanied by an increased
number of activated inflammatory cells in the respiratory
tract exhale more H2O2 and volatile lipid peroxidation
products such as ethane, pentane and TBARs. It wasTable 3. Correlations between H2O2 and TBAR concentrations in expired breath condensate and selected clinical parameters
in the whole COPD group and particulate subgroups (current smokers, ex-smokers, never smoked)
Clinical parameter
Whole group Current smokers Ex-smokers Never smoked
H2O2 TBARs H2O2 TBARs H2O2 TBARs H2O2 TBARs
FEV1 (%) 0·40** "0·02 "0·30 "0·22 0·51* "0·24 0·60* 0·56*
FEV1/FVC 0·30* 0·01 "0·42 "0·23 0·40 "0·06 0·45 0·34
Disease duration "0·15 0·23 "0·44 0·49 "0·33 0·56** 0·23 0·32
Present cigarette consumption ND ND "0·09 "0·19 ND ND ND ND
Cumulative cigarette consumption ND ND 0·12 "0·30 "0·04 "0·14 ND ND
Number of exacerbations per year "0·08 0·06 0·51 0·03 "0·09 0·09 "0·37 0·02
*P<0·05; **P<0·01.
FVC, forced vital capacity; ND, not determined.
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(20,24–26), pneumonia (25), bronchial asthma (12,27,28)
and also for asymptomatic cigarette smokers (10,13,29).
Alveolar macrophages and polymorphonuclear leukocytes
seem to be the main source of exhaled H2O2 in persons
exposed to cigarette smoke. Both asymptomatic cigarette
smokers and subjects with COPD have increased number of
these cells in bronchoalveolar lavage fluid (2,3,30). They are
activated and produce more reactive oxygen species includ-
ing H2O2 than cells obtained from healthy nonsmoking
subjects (2,3). H2O2 may also originate from type II
pneumocytes, lung microsomes and mitochondria (21,31).
As COPD patients use drugs which inhibit cellular response
to inflammatory mediators (32,33) the exhalation of H2O2
and TBARs could be even higher after cessation of this
medication.
Cigarette smoke contains many reactive oxygen species
and an aqueous solution of cigarette smoke generates H2O2
(34,35). COPD smokers refrained from smoking for 12 h
before condensate collection. Therefore, it seems that the
H2O2 measured in breath condensate did not originate
directly from cigarette smoke. There is catalase activity in
the alveolar lining fluid (36) which could decompose
cigarette smoke-derived H2O2 during the 12 h preceding
condensate collection. In addition exhaled ethane (an
alkene by-product of lipid peroxidation) decreased to base-
line at 3 h after the last cigarette in cigarette smokers, but
this value was still higher than that of subjects who had
never smoked (29).
The eVect of chronic cigarette smoking on the metabolic
activity of pulmonary phagocytes and free-radical mediated
processes may persist for a long time in ex-smokers (37,38).
Former smokers had a higher annual decline in FEV1 than
healthy subjects who had never smoked (39) and post-
mortem histopathological examination of the bronchial
walls of COPD ex-smokers showed distinct signs of
inflammation and eosinophilic infiltration (40).
Thus, ex-smokers, especially those suVering from COPD
[they represent populations susceptible to eVects of smok-
ing (41)] may reveal increased oxidant generation in the
airways as a consequence of previous cigarette smoking.
The COPD subjects who had never smoked had been
working for many years in a dusty environment. In
response to dust particles pulmonary phagocytes release
inflammatory mediators and reactive oxygen species (42)
that may result in increased exhalation of H2O2 and
TBARs.
MDA is one of the most important volatile TBARs. It
is recognized as an end-product of polyunsaturated
fatty acid peroxidation; however, it could be formed during
oxidative injury of DNA, proteins or carbohydrates (9).
Hence, elevated TBARs levels in expired breath conden-
sate of COPD subjects may reflect the increased intensity
of peroxidative damage to lung tissue. The presence of
H2O2 in expired breath condensate may be a result
of several processes, including production of H2O2, its
diVusion through cell membranes, reactions with various
biomolecules, decomposition by catalase or glutathione
peroxidase and evaporation from the alveolar lining
fluid. Higher exhalation of H2O2 may reflect its higherproduction and risk of peroxidative damage to lung tissue
with formation of volatile TBARs. On the other hand, the
decrease in exhaled H2O2 may result from its higher con-
version into hydroxyl radicals with subsequent generation
of TBARs in pulmonary parenchyma. In addition, pulmon-
ary glutathione and activity of antioxidant enzymes may
rise in response to chronic inflammatory processes and
exposition of airways to cigarette smoke (15,30). These may
explain the lack of association between exhaled H2O2 and
TBARs in the whole COPD group and also no significant
eVect of current cigarette smoking on these two variables. It
is consistent with previous studies showing no correlation
between exhaled ethane and H2O2 and smoking measures in
cigarette smokers (10,13). However, analysis of breath
condensate obtained from COPD subjects who had never
smoked showed a strong positive correlation between
H2O2 and TBARs, which is consistent with our previous
observations in nonsmoking asthmatics (12).
The rate of negative H2O2 readings in COPD group was
only 1·8-fold lower than that in healthy controls and 36% of
COPD subjects had no detectable H2O2 in their breath
condensate. Surprisingly, COPD subjects with detectable
H2O2 did not exhale more TBARs than those with negative
H2O2 readings. This may suggest that some TBARs origi-
nate from enzymatic (i.e. independent of free radical) lipid
peroxidation which is usually enhanced in sites of inflam-
mation (9), and/or that the exhaled H2O2 mostly represents
a pool of reactive oxygen species not involved in free
radical-mediated reactions leading to lipid peroxidative
damage. This H2O2 pool may be released into the epithelial
lining fluid and evaporate before the induction of lung lipid
peroxidative damage. On the other hand, the rate of COPD
subjects with both H2O2 and TBARs negative readings was
3·25 times lower than that in healthy control group. This
indicates that simultaneous measurement of H2O2 and
TBARs more eVectively distinguishes the samples of
expired breath condensate obtained from COPD subjects
and healthy controls (Fig. 3).
Neither H2O2 nor TBARs correlated with spirometric
parameters in the whole COPD group. However, in
ex-smokers and COPD subjects who had never smoked,
TBARs and H2O2 correlated positively with FEV1. Subjects
with higher FEV1 levels may represent those with lower
inflammatory damage to lung tissue and perhaps a lower
secondary rise in antioxidant enzymes activities. It has been
proved that cytokines and endotoxin can upregulate the
pulmonary antioxidant defence (43–45). On the other hand,
our previous studies have showed a negative correlation
between TBARs, H2O2 and FEV1 in asthmatics (12) and
this discrepancy may result from the diVerent natures of
these diseases. In conclusion, we found that patients with
stable COPD had elevated TBAR and H2O2 concentrations
in their expired breath condensate. This may reflect oxidant
overload in the airways and peroxidative damage to lung
tissue in COPD subjects. Neither parameter correlated with
cigarette smoking status and the majority of clinical par-
ameters. Although measurement of TBARs and H2O2 was
able to distinguish COPD subjects from healthy controls,
this approach failed to find any diVerences between the
COPD subgroups of current smokers, former smokers
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